Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 30% of the time (96 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-02-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: breast cancerstagepatient haswomenpatients
  Phrases that lowered it: insulindiabetesmellitusallergicglucose
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 5.1% (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor's past trials: 257 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 242 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 13.6% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 98.6% (raises risk) · Drug's FDA history
• Disease area, dermatology: Yes (raises risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Sponsor type: government (raises risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Keywords listed: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer NCT00678769 · started 2008 · scored riskier than 28% of active trials completed
• Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer NCT00684983 · started 2008 · scored riskier than 58% of active trials completed
• Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma NCT01016015 · started 2009 · scored riskier than 61% of active trials completed
• Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer NCT01031446 · started 2009 · scored riskier than 98% of active trials completed
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer NCT04108858 · started 2021 · scored riskier than 94% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.